Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat

Cat. No.:	HY-P1240
CAS No.:	149635-73-4
Molecular Formula:	$C_{118}H_{177}N_{35}O_{29}S$
Molecular Weight:	2581.95
Sequence Shortening:	MEVGWYRSPFSRVVHLYRNGK
Target:	Others
Pathway:	Others
Storage:	Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

BIOLOGICAL ACTIVITY

Description

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination[1][2][3].

In Vitro

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55); 0-50 μg/mL; 72 h; lymph nodes cells) induces T cell proliferative and secretes Th1 cytokines including IFN-γ, TNF-α, IL-10, IL-4 and IL-5. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat increases the level of IgG[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat can be used in animal modeling to construct mouse encephalomyelitis model.

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55); 200 μg (0.2 mL); i.p.; once, for 38 d) has encephalitogenic activity in HLA-DR2 (DRB1*1501) mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HLA-DR2 (DRB1*1501) mice[1]
Dosage:	200 μg (0.2 mL)
Administration:	Intraperitoneal injection; once, for 38 days
Result:	Resulted in paralysis of both hind and forelimbs.

CUSTOMER VALIDATION

- Cell Death Dis. 2022 Sep 2;13(9):759.
- Acta Physiol. 2023 Apr 25.
- Int Immunopharmacol. 2022 Jan 29;105:108566.
- Research Square Print. September 28th, 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Rich C, et, al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol. 2004 May;34(5):1251-61.

[2]. Slavin A, et, al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity. 1998;28(2):109-20.

[3]. Giralt M, et, al. Active Induction of Experimental Autoimmune Encephalomyelitis (EAE) with MOG35-55 in the Mouse. Methods Mol Biol. 2018;1791:227-232.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA